July 12, 2010 (Lure, France) – Vétoquinol and Orsco Laboratoire Vétérinaire today announced the signature of an exclusive contract for the distribution of Zylkene® in North America.

Like their owners, companion animals can be exposed to stressful situations, such as being adopted, weaned or hospitalised, changing owners, moving to a new home, or reproducing. The failure to adjust to such new situations in a reasonable period of time can result in the development of behavioural problems, such as feeding or digestive problems, inappropriate urination or defecation, destructive behaviour, running away, or aggressiveness.

Zylkene®, which contains a patented decapeptide, was developed to help companion animals overcome periods of stress. Zylkene® is very well tolerated, is non-habit forming, and has no rebound effect. Its effectiveness has been demonstrated in a number of clinical studies in dogs and cats. It is protected by patent, in particular in the United States.

Zylkene® has been marketed in Europe since 2006. During that time, it has become one of the leading products used to help manage stress in companion animals.

“This is a exceptional opportunity for Orsco and Vétoquinol. The American market has the world’s highest rate of provision of medical care for companion animals. We estimate that nearly 10% of all dogs and cats suffer from behavioural disorders. Zylkene® has proven its value to veterinarians in Europe, and we are confident that it can have the same success in North America. This agreement enables us to expand our portfolio of innovative products marketed by our sales representatives in North America, which is the largest animal health market in the world, and a key region in the Group’s overall growth strategy” stated Matthieu FRECHIN, CEO of Vétoquinol.

Press release